A New Era of Care: What to Expect from Synapticure in 2025 and Beyond

Sandra Abrevaya, CEO and Co-founder of Synapticure, shares the company's plans for the future after announcing the successful completion of their $25M Series A funding.

Announcing a New Advisory Relationship with The Michael J. Fox Foundation

Synapticure announces The Michael J. Fox Foundation as its newest advisor to help improve access to specialty care and to accelerate Parkinson’s research.

Synapticure Launches an IRB-Approved Study for Presymptomatic Carriers of Pathogenic, ALS-Associated Gene Variants

Synapticure Patient Panel - 01/12/23

Improving outcomes and accelerating treatments through data-driven, remote, proactive care